OKYO Pharma Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| OKYO | KPRX | OKUR | OSTX | 1477.HK | YDES | |
|---|---|---|---|---|---|---|
| Market cap | 75.05M | 7.34M | 104.89M | 53.83M | 4.05B | 492.28M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.2 | -0.7 | -1.7 | 3.3 | 17.3 | — |
| Price/book | 6.1 | 0.6 | 0.6 | -4.4 | 1.0 | 110.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −45.63% | −28.45% | −18.04% | −36.81% | −40.60% | −26.14% |
| Today | −1.38% | −4.05% | +3.60% | −0.86% | +0.30% | +7.84% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All OKYO news ›OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Stock Short Interest Rises 121.3%
Posted by Michael Walen on Oct 31st, 2026 Get Our Latest Report on OKYO Shares of NASDAQ:OKYO traded down $0.03 on Friday, reaching $1.47. 107,513 shares of the company traded hands, compared to its average volume of 47,948. The business’s…
Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain
OpenWorld (NASDAQ: OPNW) Signs Definitive Merger Agreement to Acquire Blocksight Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 Red Cat…
Small cap wrap: OKYO Pharma, 1911 Gold, TNR Gold, Standard Uranium...
First Graphene Ltd (ASX:FGR, OTCQB:FGPHF) has secured its first production order from US-based Flux Footwear, marking the company’s entry into the global sporting and athletic footwear market with its PureGRAPH graphene products. Flux will…
Oculis to Present Licaminlimab Data at AAO 2026 Meeting
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends. Oculis to Present Licaminlimab Data at AAO 2026 Meeting Oculis’s…
OKYO Pharma Begins Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain
Proactive has a commercial relationship with OKYO Pharma Ltd. This article was produced independently under Proactive's Editorial Standards Policy. OKYO Pharma’s CEO Robert Dempsey joined Steve Darling from Proactive to announce a major…
More from 3 other outlets
- Quiver Quantitative OKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain
- Stock Titan OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
- Pluang OKYO Pharma starts Phase 3 trial for neuropathic corneal pain drug urcosimod
OliPass Discloses Painful but Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002
Nov 13, 2023, 09:00 ET 1. Stage 1 Open Label Study 2. Stage 2 Placebo-controlled Double Blind Study 3. Executive Summary of Phase 2a Studies Provided below are the observed clinical findings of excessive placebo effect from the Phase 2a…
OKYO Pharma starts Phase 3 urcosimod patient enrollment
Apogee Enterprises Reports Fiscal 2027 Second Quarter Results NEPTUNE will assess ocular pain after 12 weeks of dosing, with quality-of-life scores and in-vivo confocal microscopy also included as efficacy measures. OKYO Pharma Ltd (OKYO)…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- proactiveinvestors.com3
- stocktitan.net3
- quiverquant.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.